Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Prevnar Family by Quarter
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — U.S. reported YoY (%) (%)
Pfizer Prevnar Family: -13.0% in Q2 2026, down 16.0 pts from a year earlier.
Latest, Q2 2026
-13.0%
Period ended Jun 28, 2026
Change on a year earlier
-16.0 pts
3.0% in Q2 2025
History
35 quarters
Since Q4 2017
Sources
35
Documents cited below
Where the Q2 2026 figure comes from
“|| Prevnar family (c) | 1,337 | 1,383 | (3%) | (4%) | 748 | 860 | (13%) | 589 | 523 | 13% | 10%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Prevnar Family (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/prevnar-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.